450 related articles for article (PubMed ID: 11684211)
1. Cardiovascular protection and blood pressure reduction: a meta-analysis.
Staessen JA; Wang JG; Thijs L
Lancet; 2001 Oct; 358(9290):1305-15. PubMed ID: 11684211
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003.
Staessen JA; Wang JG; Thijs L
J Hypertens; 2003 Jun; 21(6):1055-76. PubMed ID: 12777939
[TBL] [Abstract][Full Text] [Related]
3. Do ancillary properties of antihypertensive drugs explain the outcome results of recent trials?
Staessen JA; Wang J
J Nephrol; 2002; 15(4):422-7. PubMed ID: 12243374
[TBL] [Abstract][Full Text] [Related]
4. Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials.
Staessen JA; Li Y; Thijs L; Wang JG
Hypertens Res; 2005 May; 28(5):385-407. PubMed ID: 16156503
[TBL] [Abstract][Full Text] [Related]
5. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials.
Pahor M; Psaty BM; Alderman MH; Applegate WB; Williamson JD; Cavazzini C; Furberg CD
Lancet; 2000 Dec; 356(9246):1949-54. PubMed ID: 11130522
[TBL] [Abstract][Full Text] [Related]
6. Blood pressure lowering, not vascular mechanism of action, is the primary determinant of clinical outcome.
Leenen FH
Can J Cardiol; 2004 Aug; 20 Suppl B():77B-82B. PubMed ID: 15309209
[TBL] [Abstract][Full Text] [Related]
7. Effects of antihypertensive treatment in Asian populations: a meta-analysis of prospective randomized controlled studies (CARdiovascular protectioN group in Asia: CARNA).
Yano Y; Briasoulis A; Bakris GL; Hoshide S; Wang JG; Shimada K; Kario K
J Am Soc Hypertens; 2014 Feb; 8(2):103-16. PubMed ID: 24157055
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2.
Ekbom T; Linjer E; Hedner T; Lanke J; De Faire U; Wester PO; Dahlöf B; Scherstén B
Blood Press; 2004; 13(3):137-41. PubMed ID: 15223721
[TBL] [Abstract][Full Text] [Related]
9. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis.
Ettehad D; Emdin CA; Kiran A; Anderson SG; Callender T; Emberson J; Chalmers J; Rodgers A; Rahimi K
Lancet; 2016 Mar; 387(10022):957-967. PubMed ID: 26724178
[TBL] [Abstract][Full Text] [Related]
10. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies.
Law MR; Morris JK; Wald NJ
BMJ; 2009 May; 338():b1665. PubMed ID: 19454737
[TBL] [Abstract][Full Text] [Related]
11. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
Oparil S; Bakir SE
Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure.
Asayama K; Ohkubo T; Metoki H; Obara T; Inoue R; Kikuya M; Thijs L; Staessen JA; Imai Y;
Hypertens Res; 2012 Nov; 35(11):1102-10. PubMed ID: 22895063
[TBL] [Abstract][Full Text] [Related]
13. 'Beyond blood pressure' means multiple risk factor intervention, not pleiotropic antihypertensive drugs.
Staessen JA; Thijs L; Li Y; Kuznetsova T; Richart T; Wang J; Birkenhäger WH
Curr Opin Cardiol; 2007 Jul; 22(4):335-43. PubMed ID: 17556887
[TBL] [Abstract][Full Text] [Related]
14. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials.
Law MR; Wald NJ; Morris JK; Jordan RE
BMJ; 2003 Jun; 326(7404):1427. PubMed ID: 12829555
[TBL] [Abstract][Full Text] [Related]
15. Primary and secondary prevention of stroke by antihypertensive drug treatment.
Wang JG; Li Y
Expert Rev Neurother; 2004 Nov; 4(6):1023-31. PubMed ID: 15853529
[TBL] [Abstract][Full Text] [Related]
16. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection?
Ong HT
J Am Board Fam Med; 2009; 22(6):686-97. PubMed ID: 19897698
[TBL] [Abstract][Full Text] [Related]
17. Randomized controlled trials of blood pressure lowering in hypertension: a critical reappraisal.
Zanchetti A; Thomopoulos C; Parati G
Circ Res; 2015 Mar; 116(6):1058-73. PubMed ID: 25767290
[TBL] [Abstract][Full Text] [Related]
18. Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: a meta-analysis of randomised trials.
; Ying A; Arima H; Czernichow S; Woodward M; Huxley R; Turnbull F; Perkovic V; Neal B
Lancet; 2015 Mar; 385(9971):867-74. PubMed ID: 25468168
[TBL] [Abstract][Full Text] [Related]
19. Hypertension treatment and implications of recent cardiovascular outcome trials.
Weber MA
J Hypertens Suppl; 2006 Apr; 24(2):S37-44. PubMed ID: 16601560
[TBL] [Abstract][Full Text] [Related]
20. Discordant effects of beta-blockade on central aortic systolic and brachial systolic blood pressure: considerations beyond the cuff.
Epstein BJ; Anderson S
Pharmacotherapy; 2007 Sep; 27(9):1322-33. PubMed ID: 17723086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
